PKM2 is not required for pancreatic ductal adenocarcinoma

PKM2 is not required for pancreatic ductal adenocarcinoma

Background While most cancer cells preferentially express the M2 isoform of the glycolytic enzyme pyruvate kinase (PKM2), PKM2 is dispensable for tumor development in several mouse cancer models. PKM2 is expressed in human pancreatic cancer, and there have been conflicting reports o...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Danai, Laura V, Di Vizio, Dolores, Hillis, Alissandra L., Lau, Allison N., Devoe, Camille X., Vander Heiden, Matthew G., Dayton, Talya Lucia
Altri autori:	Massachusetts Institute of Technology. Department of Biology
Natura:	Articolo
Lingua:	English
Pubblicazione:	BioMed Central Ltd 2018
Accesso online:	http://hdl.handle.net/1721.1/118876 https://orcid.org/0000-0003-4250-7355 https://orcid.org/0000-0002-7994-7963 https://orcid.org/0000-0002-6702-4192

Documenti analoghi

PKM2 is not required for colon cancer initiated by APC loss
di: Sinnamon, Mark J, et al.
Pubblicazione: (2018)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
di: Lau, Allison N, et al.
Pubblicazione: (2021)

Examining the roles of the pyruvate kinase isoforms, PKMI1 and PKM2, in systemic metabolism and tumor development
di: Dayton, Talya Lucia
Pubblicazione: (2016)

Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells
di: Tian, Chenxi, et al.
Pubblicazione: (2021)

Phenotypic selection with an intrabody library reveals an anti-apoptotic function of PKM2 requiring Mitofusin-1
di: Vander Heiden, Matthew G.
Pubblicazione: (2020)

Identifying genes that are required for the maintenance of pancreatic ductal adenocarcinoma
di: Jenq, Harry
Pubblicazione: (2013)

Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma
di: Dayton, Talya L., et al.
Pubblicazione: (2018)

Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma
di: Grace Wu, et al.
Pubblicazione: (2025-02-01)

Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development
di: Mayers, Jared R., et al.
Pubblicazione: (2015)

THE SUBTYPES OF PANCREATIC DUCTAL ADENOCARCINOMAS
di: Apeksha Kakkar, et al.
Pubblicazione: (2016-12-01)

PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells
di: Li, Jie, et al.
Pubblicazione: (2017)

Small Molecule Activation of PKM2 in Cancer Cells Induces Serine Auxotrophy
di: Vander Heiden, Matthew G.
Pubblicazione: (2014)

The T cell architecture of pancreatic ductal adenocarcinoma
di: Sivakumar, S, et al.
Pubblicazione: (2019)

The T-cell architecture of pancreatic ductal adenocarcinoma
di: Sivakumar, S, et al.
Pubblicazione: (2019)

Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma
di: Clish, Clary B., et al.
Pubblicazione: (2017)

Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
di: Ole Helm, et al.
Pubblicazione: (2014-01-01)

Imaging p53 in pancreatic ductal adenocarcinoma
di: Koustoulidou, S
Pubblicazione: (2017)

MORPHOLOGICAL AND EXPRESSION FEATURES OF DUCTAL PANCREATIC ADENOCARCINOMA
di: Yu. Yu. Rakina, et al.
Pubblicazione: (2017-09-01)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
di: Shigenori Ei, et al.
Pubblicazione: (2023-09-01)

Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement protein A1
di: Fangyue Guo, et al.
Pubblicazione: (2024-01-01)

An unusual pAIR: Anti-PKM2 antibody and occult pancreatic adenocarcinoma
di: Meredith P. Spitz, et al.
Pubblicazione: (2024-12-01)

Lack of Evidence for PKM2 Protein Kinase Activity
di: Hosios, Aaron Marc, et al.
Pubblicazione: (2016)

The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma
di: Wang, L, et al.
Pubblicazione: (2015)

Imaging p53 in Pancreatic Ductal Adenocarcinoma (PDAC)
di: Koustoulidou, S, et al.
Pubblicazione: (2016)

Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma
di: Chelsae R. Watters, et al.
Pubblicazione: (2025-03-01)

Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma
di: Peiyi Liu, et al.
Pubblicazione: (2024-11-01)

Diagnosis of Pancreatic Ductal Adenocarcinoma Using Deep Learning
di: Fulya Kavak, et al.
Pubblicazione: (2024-10-01)

Cellular crosstalk of regulatory T cells in pancreatic ductal adenocarcinoma
di: Xuqing Shi, et al.
Pubblicazione: (2024-06-01)

Role of Endoscopic Ultrasound in Diagnosis of Pancreatic Ductal Adenocarcinoma
di: Abhirup Chatterjee, et al.
Pubblicazione: (2023-12-01)

Molecular characteristics of early‐onset pancreatic ductal adenocarcinoma
di: Silvana Debernardi, et al.
Pubblicazione: (2024-03-01)

Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression
di: Nayela N. Chowdhury, et al.
Pubblicazione: (2024-01-01)

Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions
di: Olivares, Orianne, et al.
Pubblicazione: (2018)

Immunohistochemical Evaluation of the Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma
di: Gelu Mihai Breaza, et al.
Pubblicazione: (2025-03-01)

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes
di: De Santiago, I, et al.
Pubblicazione: (2019)

Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Metaanalysis of transcriptional subtypes
di: De Santiago, I, et al.
Pubblicazione: (2018)

Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
di: Heng‐Chung Kung, et al.
Pubblicazione: (2023-04-01)

Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
di: Florian Gebauer, et al.
Pubblicazione: (2017-01-01)

Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
di: Caroline Y. K. Fong, et al.
Pubblicazione: (2019-01-01)

Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection.
di: Toshitaka Sugawara, et al.
Pubblicazione: (2021-01-01)

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma
di: Mathilde Resell, et al.
Pubblicazione: (2025-02-01)